CG Oncology's cretostimogene combo hits 96% early bladder cancer control
CORE-008 Cohort CX paired cretostimogene with gemcitabine in high-risk bladder cancer, and CG Oncology now owes the field durability data to show the early signal holds.
Executive Summary
- CG Oncology has posted an interim readout for its intravesical combination cohort, showing high response rates and a clean safety profile in a hard-to-treat bladder cancer population, and the pending update will test whether that signal holds over longer follow-up.
- The combination regimen is designed to extend the profile the company has already built with its single-agent virotherapy, so durability data determines whether the combination adds value beyond monotherapy or just adds a chemotherapy partner without lasting benefit.
- The asset is the only industry trial combining this mechanism with chemotherapy in this population, sitting in a field where trial activity targeting the same biology has slowed sharply, which narrows the read to this program's own data rather than a head-to-head comparison.
- The trial's enrollment target has held steady at capacity and its status remains normal for an actively recruiting study, so execution is not the open question; the open question is whether the mid-2026 durability signal repeats the interim numbers.
The interim readout
CG Oncology reported first results from CORE-008 Cohort CX on May 15, 2026, showing an intravesical combination of cretostimogene grenadenorepvec and gemcitabine produced high-grade event-free survival of 96% at 3 months and 89.5% at 6 months in the intent-to-treat population, with a median follow-up of 6.6 months. Complete response rates at any time reached 85.7% (24 of 28 patients) in the intent-to-treat population and 92.3% (24 of 26 patients) in the efficacy-evaluable population, both in patients with carcinoma in situ. Vijay Kasturi, Chief Medical Officer of CG Oncology, said Cohort CX "was designed to assess whether combining cretostimogene with gemcitabine can further extend the strong clinical profile we have established with cretostimogene monotherapy" and that the company "looks forward to sharing durability data later this year". CGCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating ...May 15, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Safety and population
No Grade 3 or greater treatment-related adverse events or deaths were reported across the cohort, which was 65.6% BCG-exposed and 34.5% BCG-unresponsive, with more than 80% of patients treated in community practices. Efficacy was comparable across concurrent and sequential dosing schedules and across both BCG-exposed and BCG-unresponsive subgroups, according to the disclosed analysis. The trial runs under NCT06567743, a randomized, multi-arm, multi-cohort Phase 2 study enrolling 325 patients across cohorts testing complete response rate and high-grade event-free survival as primary endpoints depending on cohort and arm. CG+1CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating ...May 15, 2026Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743
Trial operations
The study has held its 325-patient enrollment target since May 2025, after two upward revisions from an original 50-patient plan as the design expanded to its current multi-cohort structure, and remains in Recruiting status with a primary completion date of March 31, 2027. The registered guidance for the durability catalyst has moved from a full-year 2026 window to a narrower July-to-December 2026 window as of the May 2026 disclosure, consistent with the interim data now needing a longer follow-up cut before a durability readout is possible. NCT06567743+1Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating ...May 15, 2026
The competitive frame
Cretostimogene grenadenorepvec is the only industry-sponsored asset targeting RB1 pathway biology in high-risk non-muscle invasive bladder cancer at Phase 2 or beyond, and the closest comparator in the modality is the same drug's own Phase 3 program (NCT04452591), also run by CG Oncology. Trial activity in RB1-targeted programs for this indication has slowed, with 1 recent trial against 9 older ones, and the broader oncolytic-virus field in bladder cancer includes only a small number of active industry programs. That leaves the durability update to be judged mainly against the company's own interim numbers rather than against a competing regimen.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.